Kerri J. Kinghorn

Kerri J. Kinghorn

Auto-generated profile, based on publicly available information

Kerri J. Kinghorn

UCL Institute of Healthy Ageing, Department of Genetics, Evolution and Environment, University College London

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
MNMike A Nalls
Mike A Nalls
CBCornelis Blauwendraat
Cornelis Blauwendraat
KHKarl Heilbron
Karl Heilbron
SBSara Bandres-Ciga
Sara Bandres-Ciga
DCDiana Chang
Diana Chang
FZFutao Zhang
Futao Zhang

1 January 2005 in Neuroscience
Verified
Journal Article
Closed access
DCD.C. Crowther
D.C. Crowther
KKK.J. Kinghorn
K.J. Kinghorn
Elena MirandaElena Miranda
Elena Miranda
RPR. Page
R. Page
JCJ.A. Curry
J.A. Curry
DLD.A. Lomas
D.A. Lomas

22 May 2015 in Brain
Verified
Journal Article
Open access
PDF file
KKKerri J. Kinghorn
Kerri J. Kinghorn
JCJorge Iván Castillo-Quan
Jorge Iván Castillo-Quan
FBFernando Bartolome
Fernando Bartolome
PAPlamena R. Angelova
Plamena R. Angelova
LLLi Li
Li Li
LPLinda Partridge
Linda Partridge
The PLA2G6 gene encodes a group VIA calcium-independent phospholipase A2 beta enzyme that selectively hydrolyses glycerophospholipids to release free fatty acids. Mutations in PLA2G6 have been associated with disorders such as infantile neuroaxonal dystrophy, neurodegeneration with brain iron accumulation type II and Karak syndrome. More recently, PLA2G6 was identified as the causative gene in a subgroup of patients with autosomal recessive early-onset dystonia-parkinsonism. Neuropathological examination revealed widespread Lewy body pathology and the accumulation of hyperphosphorylated tau, supporting a link between PLA2G6 mutations and parkinsonian disorders. Here we show that knockout of the Drosophila homologue of the PLA2G6 gene, iPLA2-VIA, results in reduced survival, locomotor deficits and organismal hypersensitivity to oxidative stress. Furthermore, we demonstrate that loss of iPLA2-VIA function leads to a number of mitochondrial abnormalities, including mitochondrial respiratory chain dysfunction, reduced ATP synthesis and abnormal mitochondrial morphology. Moreover, we show that loss of iPLA2-VIA is strongly associated with increased lipid peroxidation levels. We confirmed our findings using cultured fibroblasts taken from two patients with mutations in the PLA2G6 gene. Similar abnormalities were seen including elevated mitochondrial lipid peroxidation and mitochondrial membrane defects, as well as raised levels of cytoplasmic and mitochondrial reactive oxygen species. Finally, we demonstrated that deuterated polyunsaturated fatty acids, which inhibit lipid peroxidation, were able to partially rescue the locomotor abnormalities seen in aged flies lacking iPLA2-VIA gene function, and restore mitochondrial membrane potential in fibroblasts from patients with PLA2G6 mutations. Taken together, our findings demonstrate that loss of normal PLA2G6 gene activity leads to lipid peroxidation, mitochondrial dysfunction and subsequent mitochondrial membrane abnormalities. Furthermore we show that the iPLA2-VIA knockout fly model provides a useful platform for the further study of PLA2G6-associated neurodegeneration.

1 April 2016 in Cell Reports
Verified
Journal Article
Open access
JCJorge Iván Castillo-Quan
Jorge Iván Castillo-Quan
LLLi Li
Li Li
KKKerri J. Kinghorn
Kerri J. Kinghorn
DIDobril K. Ivanov
Dobril K. Ivanov
LTLuke S. Tain
Luke S. Tain
LPLinda Partridge
Linda Partridge
The quest to extend healthspan via pharmacological means is becoming increasingly urgent, both from a health and economic perspective. Here we show that lithium, a drug approved for human use, promotes longevity and healthspan. We demonstrate that lithium extends lifespan in female and male Drosophila, when administered throughout adulthood or only later in life. The life-extending mechanism involves the inhibition of glycogen synthase kinase-3 (GSK-3) and activation of the transcription factor nuclear factor erythroid 2-related factor (NRF-2). Combining genetic loss of the NRF-2 repressor Kelch-like ECH-associated protein 1 (Keap1) with lithium treatment revealed that high levels of NRF-2 activation conferred stress resistance, while low levels additionally promoted longevity. The discovery of GSK-3 as a therapeutic target for aging will likely lead to more effective treatments that can modulate mammalian aging and further improve health in later life.

16 November 2016 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KKKerri J. Kinghorn
Kerri J. Kinghorn
SGSebastian Grönke
Sebastian Grönke
JCJorge Iván Castillo-Quan
Jorge Iván Castillo-Quan
NWNathaniel S. Woodling
Nathaniel S. Woodling
LLLi Li
Li Li
LPLinda Partridge
Linda Partridge
Glucocerebrosidase (GBA1) mutations are associated with Gaucher disease (GD), an autosomal recessive disorder caused by functional deficiency of glucocerebrosidase (GBA), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. Neuronopathic forms of GD can be associated with rapid neurological decline (Type II) or manifest as a chronic form (Type III) with a wide spectrum of neurological signs. Furthermore, there is now a well-established link betweenGBA1mutations and Parkinson's disease (PD), with heterozygote mutations inGBA1considered the commonest genetic defect in PD. Here we describe a novelDrosophilamodel of GD that lacks the two flyGBA1orthologs. This knock-out model recapitulates the main features of GD at the cellular level with severe lysosomal defects and accumulation of glucosylceramide in the fly brain. We also demonstrate a block in autophagy flux in association with reduced lifespan, age-dependent locomotor deficits and accumulation of autophagy substrates in dGBA-deficient fly brains. Furthermore, mechanistic target of rapamycin (mTOR) signaling is downregulated in dGBA knock-out flies, with a concomitant upregulation ofMitfgene expression, the fly ortholog of mammalianTFEB, likely as a compensatory response to the autophagy block. Moreover, the mTOR inhibitor rapamycin is able to partially ameliorate the lifespan, locomotor, and oxidative stress phenotypes. Together, our results demonstrate that thisdGBA1-deficient fly model is a useful platform for the further study of the role of lysosomal-autophagic impairment and the potential therapeutic benefits of rapamycin in neuronopathic GD. These results also have important implications for the role of autophagy and mTOR signaling in GBA1-associatedPD.SIGNIFICANCE STATEMENTWe developed aDrosophilamodel of neuronopathic GD by knocking-out the fly orthologs of theGBA1gene, demonstrating abnormal lysosomal pathology in the fly brain. Functioning lysosomes are required for autophagosome-lysosomal fusion in the autophagy pathway. We showin vivothat autophagy is impaired in dGBA-deficient fly brains. In response, mechanistic target of rapamycin (mTOR) activity is downregulated in dGBA-deficient flies and rapamycin ameliorates the lifespan, locomotor, and oxidative stress phenotypes.dGBAknock-out flies also display an upregulation of theDrosophilaortholog of mammalianTFEB,Mitf,a response that is unable to overcome the autophagy block. Together, our results suggest that rapamycin may have potential benefits in the treatment of GD, as well as PD linked toGBA1mutations.

8 July 2011 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
PDPelagia Deriziotis
Pelagia Deriziotis
RARalph André
Ralph André
DSDavid M. Smith
David M. Smith
RGRob Goold
Rob Goold
KKKerri J Kinghorn
Kerri J Kinghorn
STSarah J Tabrizi
Sarah J Tabrizi
Prion diseases are associated with the conversion of cellular prion protein (PrPC) to toxic β‐sheet isoforms (PrPSc), which are reported to inhibit the ubiquitin‐proteasome system (UPS). Accordingly, UPS substrates accumulate in prion‐infected mouse brains, suggesting impairment of the 26S proteasome. A direct interaction between its 20S core particle and PrP isoforms was demonstrated by immunoprecipitation. β‐PrP aggregates associated with the 20S particle, but did not impede binding of the PA26 complex, suggesting that the aggregates do not bind to its ends. Aggregated β‐PrP reduced the 20S proteasome's basal peptidase activity, and the enhanced activity induced by C‐terminal peptides from the 19S ATPases or by the 19S regulator itself, including when stimulated by polyubiquitin conjugates. However, the 20S proteasome was not inhibited when the gate in the α‐ring was open due to a truncation mutation or by association with PA26/PA28. These PrP aggregates inhibit by stabilising the closed conformation of the substrate entry channel. A similar inhibition of substrate entry into the proteasome may occur in other neurodegenerative diseases where misfolded β‐sheet‐rich proteins accumulate.